TY  - JOUR
AU  - Olalla, Julián
AU  - Pérez-Stachowski, Javier
AU  - Tortajada, Begoña
AU  - Del Arco, Alfonso
AU  - Márquez, Efrén
AU  - De la Torre, Javier
AU  - Nieto, Miriam
AU  - García de Lomas, José María
AU  - Prada, José Luis
AU  - García-Alegría, Javier
PY  - 2018
DO  - 10.1186/s40360-018-0252-z
UR  - https://hdl.handle.net/10668/26715
T2  - BMC pharmacology & toxicology
AB  - Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical...
LA  - en
KW  - Dolutegravir drugs
KW  - Generic drugs
KW  - HAART
KW  - Substitution HIV
KW  - Anti-HIV Agents
KW  - Antiretroviral Therapy, Highly Active
KW  - Dideoxynucleosides
KW  - Drug Combinations
KW  - Drug Substitution
KW  - Drugs, Generic
KW  - Female
KW  - HIV Infections
KW  - Heterocyclic Compounds, 3-Ring
KW  - Humans
KW  - Lamivudine
KW  - Male
KW  - Middle Aged
KW  - Oxazines
KW  - Piperazines
KW  - Pyridones
KW  - Treatment Outcome
KW  - Viral Load
TI  - Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
TY  - research article
VL  - 19
ER  -